{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T14:10:24Z","timestamp":1793974224312,"version":"4.8.0"},"reference-count":64,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T00:00:00Z","timestamp":1651536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2022,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Myasthenia gravis (MG) is an autoimmune disease, for which the risk of exacerbation after vaccines is debated. The aim of this study is to review the available literature concerning safety and efficacy of vaccines in MG. In addition, we also conducted a retrospective research of MG exacerbations and new onset MG after anti-SARS-CoV-2 vaccination in a large cohort of patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A study of the available literature regarding vaccines and MG was carried out through research in the online database \u201cPubmed\u201d. We also retrospectively collected data from 80 MG patients, who were followed at the Treviso Hospital and completed an anti-SARS-CoV-2 vaccination cycle. For each patient, we recorded MG exacerbations between first and second doses and within a window period of 1\u00a0day \u2013 6\u00a0weeks after the second dose.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We found 26 relevant articles about influenza, SARS-CoV-2 and other vaccines. No clear associations between most vaccines and MG exacerbations were found. Moreover, cases of new onset post-vaccine MG are mostly anecdotal, except for Japanese encephalitis virus vaccine. Concerning our cohort, 4\/80 (5%) MG patients experienced an exacerbation within the post-vaccine window period. In addition, we report a case of new onset post-vaccine MG.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>Inactivated and subunit vaccines are safe and effective in MG. Although some of them, such as anti-SARS-CoV-2 vaccine, might uncommonly cause MG exacerbations, data from our review suggest that benefits still outweigh by far the potential risks, thus they should be recommended to these patients. Nevertheless, large prospective studies are needed for further investigations.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00415-022-11140-9","type":"journal-article","created":{"date-parts":[[2022,5,3]],"date-time":"2022-05-03T09:03:14Z","timestamp":1651568594000},"page":"3965-3981","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Vaccines and myasthenia gravis: a comprehensive review and retrospective study of SARS-CoV-2 vaccination in a large cohort of myasthenic patients"],"prefix":"10.1007","volume":"269","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3685-7108","authenticated-orcid":false,"given":"Giulio","family":"Sansone","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico Marco","family":"Bonifati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,5,3]]},"reference":[{"key":"11140_CR1","unstructured":"Ropper AH, Samuels MA, Klein JP, Prasad S (2019) Disorders of the neuromuscular junction, myotonias, and persistent muscle fiber activity. In: Moyer A, Davis KJ (eds) Adams and Victor\u2019s principles of neurology, 11th edn. McGraw Hill, pp 1469\u20131480"},{"key":"11140_CR2","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/mus.26689","volume":"60","author":"RR Gummi","year":"2019","unstructured":"Gummi RR, Kukulka NA, Deroche CB, Govindarajan R (2019) Factors associated with acute exacerbations of myasthenia gravis. Muscle Nerve 60:693\u2013699. https:\/\/doi.org\/10.1002\/mus.26689","journal-title":"Muscle Nerve"},{"key":"11140_CR3","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1111\/j.1600-0404.1989.tb03786.x","volume":"79","author":"G Magni","year":"1989","unstructured":"Magni G, Micaglio G, Ceccato MB, Lalli R, Bejato L, Angelini C (1989) The role of life events in the myasthenia gravis outcome: a one-year longitudinal study. Acta Neurol Scand 79:288\u2013291. https:\/\/doi.org\/10.1111\/j.1600-0404.1989.tb03786.x","journal-title":"Acta Neurol Scand"},{"key":"11140_CR4","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1093\/cid\/ciu005","volume":"58","author":"C Vellozzi","year":"2014","unstructured":"Vellozzi C, Iqbal S, Broder K (2014) Guillain-Barr\u00e9 syndrome, influenza, and influenza vaccination: the epidemiologic evidence. Clin Infect Dis 58:1149\u20131155. https:\/\/doi.org\/10.1093\/cid\/ciu005","journal-title":"Clin Infect Dis"},{"key":"11140_CR5","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1086\/589624","volume":"198","author":"I Nachamkin","year":"2008","unstructured":"Nachamkin I, Shadomy SV, Moran AP, Cox N, Fitzgerald C, Ung H et al (2008) Anti-ganglioside antibody induction by swine (A\/NJ\/1976\/H1N1) and other influenza vaccines: insights into vaccine-associated Guillain-Barr\u00e9 syndrome. J Infect Dis 198:226\u2013233. https:\/\/doi.org\/10.1086\/589624","journal-title":"J Infect Dis"},{"key":"11140_CR6","doi-asserted-by":"publisher","first-page":"3773","DOI":"10.1016\/j.vaccine.2015.05.013","volume":"33","author":"LH Mart\u00edn Arias","year":"2015","unstructured":"Mart\u00edn Arias LH, Sanz R, S\u00e1inz M, Trece\u00f1o C, Carvajal A (2015) Guillain-Barr\u00e9 syndrome and influenza vaccines: a meta-analysis. Vaccine 33:3773\u20133778. https:\/\/doi.org\/10.1016\/j.vaccine.2015.05.013","journal-title":"Vaccine"},{"key":"11140_CR7","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s00415-016-8263-4","volume":"264","author":"MT Mailand","year":"2017","unstructured":"Mailand MT, Frederiksen JL (2017) Vaccines and multiple sclerosis: a systematic review. J Neurol 264:1035\u20131050. https:\/\/doi.org\/10.1007\/s00415-016-8263-4","journal-title":"J Neurol"},{"key":"11140_CR8","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1007\/s00415-011-5944-x","volume":"258","author":"N McNicholas","year":"2011","unstructured":"McNicholas N, Chataway J (2011) Relapse risk in patients with multiple sclerosis after H1N1 vaccination, with or without seasonal influenza vaccination. J Neurol 258:1545\u20131547. https:\/\/doi.org\/10.1007\/s00415-011-5944-x","journal-title":"J Neurol"},{"key":"11140_CR9","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1001\/archneurol.2011.131","volume":"68","author":"MF Farez","year":"2011","unstructured":"Farez MF, Correale J (2011) Yellow fever vaccination and increased relapse rate in travelers with multiple sclerosis. Arch Neurol 68:1267\u20131271. https:\/\/doi.org\/10.1001\/archneurol.2011.131","journal-title":"Arch Neurol"},{"key":"11140_CR10","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1177\/1203475418811335","volume":"23","author":"KA Papp","year":"2019","unstructured":"Papp KA, Haraoui B, Kumar D, Marshall JK, Bissonnette R, Bitton A et al (2019) Vaccination guidelines for patients with immune-mediated disorders on immunosuppressive therapies. J Cutan Med Surg 23:50\u201374. https:\/\/doi.org\/10.1177\/1203475418811335","journal-title":"J Cutan Med Surg"},{"key":"11140_CR11","first-page":"317","volume":"1963","author":"RRA Coombs","year":"1963","unstructured":"Coombs RRA, PGHG (1963) The classification of allergic reactions underlying disease. Clin Asp Immunol 1963:317\u201337","journal-title":"Clin Asp Immunol"},{"key":"11140_CR12","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.vaccine.2010.10.044","volume":"29","author":"HC Koenig","year":"2011","unstructured":"Koenig HC, Sutherland A, Izurieta HS, McGonagle D (2011) Application of the immunological disease continuum to study autoimmune and other inflammatory events after vaccination. Vaccine 29:913\u2013919. https:\/\/doi.org\/10.1016\/j.vaccine.2010.10.044","journal-title":"Vaccine"},{"key":"11140_CR13","doi-asserted-by":"publisher","first-page":"14559","DOI":"10.1073\/pnas.0405924101","volume":"101","author":"M Sela","year":"2002","unstructured":"Sela M, Hilleman MR (2002) Therapeutic vaccines: realities of today and hopes for the future. Proc Natl Acad Sci 101:14559\u201314559. https:\/\/doi.org\/10.1073\/pnas.0405924101","journal-title":"Proc Natl Acad Sci"},{"key":"11140_CR14","doi-asserted-by":"publisher","first-page":"14586","DOI":"10.1073\/pnas.0404826101","volume":"101","author":"M Sela","year":"2004","unstructured":"Sela M, Mozes E (2004) Therapeutic vaccines in autoimmunity. Proc Natl Acad Sci U S A 101:14586\u201314592. https:\/\/doi.org\/10.1073\/pnas.0404826101","journal-title":"Proc Natl Acad Sci U S A"},{"key":"11140_CR15","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1517\/14712598.5.7.983","volume":"5","author":"S Berrih-Aknin","year":"2005","unstructured":"Berrih-Aknin S, Fuchs S, Souroujon MC (2005) Vaccines against myasthenia gravis. Expert Opin Biol Ther 5:983\u2013995. https:\/\/doi.org\/10.1517\/14712598.5.7.983","journal-title":"Expert Opin Biol Ther"},{"key":"11140_CR16","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1016\/j.bcp.2015.07.011","volume":"97","author":"J Luo","year":"2015","unstructured":"Luo J, Lindstrom J (2015) AChR-specific immunosuppressive therapy of myasthenia gravis. Biochem Pharmacol 97:609\u2013619. https:\/\/doi.org\/10.1016\/j.bcp.2015.07.011","journal-title":"Biochem Pharmacol"},{"key":"11140_CR17","doi-asserted-by":"publisher","first-page":"5044","DOI":"10.4049\/jimmunol.1401392","volume":"193","author":"J Luo","year":"2014","unstructured":"Luo J, Lindstrom J (2014) Antigen-specific immunotherapeutic vaccine for experimental autoimmune myasthenia gravis. J Immunol 193:5044\u20135055. https:\/\/doi.org\/10.4049\/jimmunol.1401392","journal-title":"J Immunol"},{"key":"11140_CR18","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1136\/jnnp-2021-326924","volume":"92","author":"M Butler","year":"2021","unstructured":"Butler M, Tamborska A, Wood GK, Ellul M, Thomas RH, Galea I et al (2021) Considerations for causality assessment of neurological and neuropsychiatric complications of SARS-CoV-2 vaccines: from cerebral venous sinus thrombosis to functional neurological disorder. J Neurol Neurosurg Psychiatry 92:1144\u20131151. https:\/\/doi.org\/10.1136\/jnnp-2021-326924","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"11140_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/mus.27224","author":"B Roy","year":"2021","unstructured":"Roy B, Litchman T, Torabi T, Nowak RJ (2021) The influenza vaccination in autoimmune neuromuscular diseases: a survey of current practices and perceptions. Muscle Nerve. https:\/\/doi.org\/10.1002\/mus.27224","journal-title":"Muscle Nerve"},{"key":"11140_CR20","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1002\/mus.21440","volume":"40","author":"L Zinman","year":"2009","unstructured":"Zinman L, Thoma J, Kwong JC, Kopp A, Stukel TA, Juurlink DN (2009) Safety of influenza vaccination in patients with myasthenia gravis: a population-based study. Muscle Nerve 40:947\u2013951. https:\/\/doi.org\/10.1002\/mus.21440","journal-title":"Muscle Nerve"},{"key":"11140_CR21","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1002\/mus.22077","volume":"43","author":"E Auriel","year":"2011","unstructured":"Auriel E, Regev K, Dori A, Karni A (2011) Safety of influenza and H1N1 vaccinations in patients with myasthenia gravis, and patient compliance. Muscle Nerve 43:893\u2013894. https:\/\/doi.org\/10.1002\/mus.22077","journal-title":"Muscle Nerve"},{"key":"11140_CR22","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3988\/jcn.2017.13.4.325","volume":"13","author":"HY Seok","year":"2017","unstructured":"Seok HY, Shin HY, Kim JK, Kim BJ, Oh J, Suh BC, Kim SY, Kang SY, Ahn SW, Bae JS, Kim BJ (2017) The impacts of influenza infection and vaccination on exacerbation of myasthenia gravis. J Clin Neurol 13:325\u2013330","journal-title":"J Clin Neurol"},{"key":"11140_CR23","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/j.vaccine.2019.01.007","volume":"37","author":"E Strijbos","year":"2019","unstructured":"Strijbos E, Tannemaat MR, Alleman I, de Meel RHP, Bakker JA, van Beek R et al (2019) A prospective, double-blind, randomized, placebo-controlled study on the efficacy and safety of influenza vaccination in myasthenia gravis. Vaccine 37:919\u2013925. https:\/\/doi.org\/10.1016\/j.vaccine.2019.01.007","journal-title":"Vaccine"},{"key":"11140_CR24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.ebiom.2018.01.007","volume":"28","author":"B Tackenberg","year":"2018","unstructured":"Tackenberg B, Schneider M, Blaes F, Eienbr\u00f6ker C, Schade-Brittinger C, Wellek A et al (2018) Acetylcholine receptor antibody titers and clinical course after influenza vaccination in patients with myasthenia gravis: a double-blind randomized controlled trial (ProPATIent-Trial). EBioMedicine 28:143\u2013150. https:\/\/doi.org\/10.1016\/j.ebiom.2018.01.007","journal-title":"EBioMedicine"},{"key":"11140_CR25","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2021.1977580","author":"F Wang","year":"2021","unstructured":"Wang F, Xiang T, He L, Wang J (2021) Laryngeal myasthenia gravis following influenza vaccination: a case report and literature review. Hum Vaccines Immunother. https:\/\/doi.org\/10.1080\/21645515.2021.1977580","journal-title":"Hum Vaccines Immunother"},{"key":"11140_CR26","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3109\/08916939908995383","volume":"29","author":"V Domigo","year":"1999","unstructured":"Domigo V, Authier FJ, Bachoud-Levi AC, Gherardi RK, Degos JD (1999) Should hepatitis B vaccine be contra-indicated in myasthenia gravis? Autoimmunity 29:139\u2013140. https:\/\/doi.org\/10.3109\/08916939908995383","journal-title":"Autoimmunity"},{"key":"11140_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jns.2010.02.016","volume":"292","author":"JP St\u00fcbgen","year":"2010","unstructured":"St\u00fcbgen JP (2010) Neuromuscular disorders associated with hepatitis B vaccination. J Neurol Sci 292:1\u20134. https:\/\/doi.org\/10.1016\/j.jns.2010.02.016","journal-title":"J Neurol Sci"},{"key":"11140_CR28","doi-asserted-by":"publisher","first-page":"2685","DOI":"10.1001\/archinte.1988.00380120123025","volume":"148","author":"P Biron","year":"1988","unstructured":"Biron P, Montpetit P, Infante Rivard C, L\u00e9ry L (1988) myasthenia gravis after general anesthesia and hepatitis B vaccine. Arch Intern Med 148:2685. https:\/\/doi.org\/10.1001\/archinte.1988.00380120123025","journal-title":"Arch Intern Med"},{"key":"11140_CR29","doi-asserted-by":"publisher","first-page":"378","DOI":"10.2515\/therapie:2003059","volume":"58","author":"B Louzir","year":"2003","unstructured":"Louzir B, Othmani S, Battikh R, Abdelhafidh NB, Bahri M, Taalouche L et al (2003) Myasthenia gravis after hepatitis B vaccine [2]. Therapie 58:378\u20139. https:\/\/doi.org\/10.2515\/therapie:2003059","journal-title":"Therapie"},{"key":"11140_CR30","doi-asserted-by":"publisher","first-page":"3876","DOI":"10.1016\/j.vaccine.2005.03.005","volume":"23","author":"A Schattner","year":"2005","unstructured":"Schattner A (2005) Consequence or coincidence? The occurrence, pathogenesis and significance of autoimmune manifestations after viral vaccines. Vaccine 23:3876\u20133886. https:\/\/doi.org\/10.1016\/j.vaccine.2005.03.005","journal-title":"Vaccine"},{"key":"11140_CR31","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1093\/oxfordjournals.aje.a114808","volume":"127","author":"FE Shaw","year":"1988","unstructured":"Shaw FE, Graham DJ, Guess HA, Milstien JB, Johnson JM, Schatz GC et al (1988) Postmarketing surveillance for neurologic adverse events reported after hepatitis b vaccination: experience of the first three years. Am J Epidemiol 127:337\u2013352. https:\/\/doi.org\/10.1093\/oxfordjournals.aje.a114808","journal-title":"Am J Epidemiol"},{"key":"11140_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12883-018-1233-y","volume":"18","author":"JY Chung","year":"2018","unstructured":"Chung JY, Lee SJ, Shin BS, Kang HG (2018) Myasthenia gravis following human papillomavirus vaccination: a case report. BMC Neurol 18:1\u20134. https:\/\/doi.org\/10.1186\/s12883-018-1233-y","journal-title":"BMC Neurol"},{"key":"11140_CR33","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1002\/ana.25267","volume":"84","author":"D He","year":"2018","unstructured":"He D, Zhang H, Xiao J, Zhang X, Xie M, Pan D et al (2018) Molecular and clinical relationship between live-attenuated Japanese encephalitis vaccination and childhood onset myasthenia gravis. Ann Neurol 84:386\u2013400. https:\/\/doi.org\/10.1002\/ana.25267","journal-title":"Ann Neurol"},{"key":"11140_CR34","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000008757","author":"T Takizawa","year":"2017","unstructured":"Takizawa T, Kojima M, Suzuki S, Osada T, Kitagawa S, Nakahara J et al (2017) New onset of myasthenia gravis after intravesical Bacillus Calmette-Guerin. Med (United States). https:\/\/doi.org\/10.1097\/MD.0000000000008757","journal-title":"Med (United States)"},{"key":"11140_CR35","doi-asserted-by":"publisher","first-page":"E1","DOI":"10.1002\/mus.26328","volume":"59","author":"L Davalos","year":"2019","unstructured":"Davalos L, Kushlaf H (2019) New onset of seropositive generalized myasthenia gravis following intravesical bacille Calmette-Guerin treatment for bladder cancer: a case study. Muscle Nerve 59:E1-2. https:\/\/doi.org\/10.1002\/mus.26328","journal-title":"Muscle Nerve"},{"key":"11140_CR36","doi-asserted-by":"publisher","first-page":"6290","DOI":"10.1016\/j.vaccine.2017.09.078","volume":"35","author":"E Strijbos","year":"2017","unstructured":"Strijbos E, Huijbers MG, van Es IE, Alleman I, van Ostaijen-ten Dam MM, Bakker J et al (2017) A prospective, placebo controlled study on the humoral immune response to and safety of tetanus revaccination in myasthenia gravis. Vaccine 35:6290\u20136296. https:\/\/doi.org\/10.1016\/j.vaccine.2017.09.078","journal-title":"Vaccine"},{"key":"11140_CR37","unstructured":"The immunological basis for immunization series: module 3: tetanus n.d. https:\/\/apps.who.int\/iris\/handle\/10665\/275340. Accessed 12 Dec 2021"},{"key":"11140_CR38","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1016\/j.molimm.2013.01.012","volume":"54","author":"D Csuka","year":"2013","unstructured":"Csuka D, Czirj\u00e1k L, H\u00f3bor R, Illes Z, B\u00e1n\u00e1ti M, Rajczy K et al (2013) Effective humoral immunity against diphtheria and tetanus in patients with systemic lupus erythematosus or myasthenia gravis. Mol Immunol 54:453\u2013456. https:\/\/doi.org\/10.1016\/j.molimm.2013.01.012","journal-title":"Mol Immunol"},{"key":"11140_CR39","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1097\/INF.0000000000001696","volume":"36","author":"SY Tartof","year":"2017","unstructured":"Tartof SY, Sy LS, Ackerson BK, Hechter RC, Haag M, Slezak JM et al (2017) Safety of quadrivalent meningococcal conjugate vaccine in children 2\u201310 years. Pediatr Infect Dis J 36:1087\u20131092. https:\/\/doi.org\/10.1097\/INF.0000000000001696","journal-title":"Pediatr Infect Dis J"},{"key":"11140_CR40","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1002\/jca.2920050304","volume":"5","author":"TJ Nasca","year":"1990","unstructured":"Nasca TJ, Muder RR, Thomas DB, Schrecker JC, Ruben FL (1990) Antibody response to pneumococcal polysaccharide vaccine in myasthenia gravis: effect of therapeutic plasmapheresis. J Clin Apher 5:133\u2013139. https:\/\/doi.org\/10.1002\/jca.2920050304","journal-title":"J Clin Apher"},{"key":"11140_CR41","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9101112","author":"Z Ruan","year":"2021","unstructured":"Ruan Z, Tang Y, Li C, Sun C, Zhu Y, Li Z et al (2021) Covid-19 vaccination in patients with myasthenia gravis: a single-center case series. Vaccines. https:\/\/doi.org\/10.3390\/vaccines9101112","journal-title":"Vaccines"},{"key":"11140_CR42","doi-asserted-by":"publisher","first-page":"13","DOI":"10.7759\/cureus.15581","volume":"13","author":"AR Tagliaferri","year":"2021","unstructured":"Tagliaferri AR, Narvaneni S, Azzam MH, Grist W (2021) A case of COVID-19 vaccine causing a myasthenia gravis crisis. Cureus 13:13\u201315. https:\/\/doi.org\/10.7759\/cureus.15581","journal-title":"Cureus"},{"key":"11140_CR43","unstructured":"Amarasinghe A, World Health Organization, Global Advisory Committee on Vaccine Safety (2014, 2016 update) Global manual on surveillance of adverse events following immunization. https:\/\/www.who.int\/publications\/i\/item\/10665206144. Accessed 8 Dec 2021"},{"key":"11140_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/vaccines9050435","volume":"9","author":"A Watad","year":"2021","unstructured":"Watad A, De Marco G, Mahajna H, Druyan A, Eltity M, Hijazi N et al (2021) Immune-mediated disease flares or new-onset disease in 27 subjects following mrna\/dna sars-cov-2 vaccination. Vaccines 9:1\u201323. https:\/\/doi.org\/10.3390\/vaccines9050435","journal-title":"Vaccines"},{"key":"11140_CR45","doi-asserted-by":"publisher","first-page":"215013272110519","DOI":"10.1177\/21501327211051933","volume":"12","author":"A Chavez","year":"2021","unstructured":"Chavez A, Pougnier C (2021) A case of COVID-19 vaccine associated new diagnosis myasthenia gravis. J Prim Care Commun Health 12:215013272110519. https:\/\/doi.org\/10.1177\/21501327211051933","journal-title":"J Prim Care Commun Health"},{"key":"11140_CR46","doi-asserted-by":"publisher","first-page":"2144","DOI":"10.1038\/s41591-021-01556-7","volume":"27","author":"M Patone","year":"2021","unstructured":"Patone M, Handunnetthi L, Saatci D, Pan J, Katikireddi SV, Razvi S et al (2021) Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nat Med 27:2144\u20132153. https:\/\/doi.org\/10.1038\/s41591-021-01556-7","journal-title":"Nat Med"},{"key":"11140_CR47","doi-asserted-by":"publisher","DOI":"10.1111\/ene.15348","author":"A Farina","year":"2022","unstructured":"Farina A, Falso S, Cornacchini S, Spagni G, Monte G, Mariottini A et al (2022) Safety and tolerability of SARS-Cov2 vaccination in patients with myasthenia gravis: a multicenter experience. Eur J Neurol. https:\/\/doi.org\/10.1111\/ene.15348","journal-title":"Eur J Neurol"},{"key":"11140_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtauto.2021.100114","volume":"4","author":"LC Plymate","year":"2021","unstructured":"Plymate LC, Pepper G, Krist MP, Koelle DM (2021) Immunogenicity of repeat COVID-19 mRNA vaccinations in a patient with myasthenia gravis receiving mycophenolate, prednisone, and eculizumab. J Transl Autoimmun 4:100114. https:\/\/doi.org\/10.1016\/j.jtauto.2021.100114","journal-title":"J Transl Autoimmun"},{"key":"11140_CR49","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1136\/annrheumdis-2021-220993","volume":"80","author":"B Golding","year":"2021","unstructured":"Golding B, Lee Y, Golding H, Khurana S (2021) Pause in immunosuppressive treatment results in improved immune response to SARS-CoV-2 vaccine in autoimmune patient: a case report. Ann Rheum Dis 80:1359\u20131361. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220993","journal-title":"Ann Rheum Dis"},{"key":"11140_CR50","doi-asserted-by":"publisher","first-page":"5893","DOI":"10.1016\/j.vaccine.2014.09.003","volume":"32","author":"S Esposito","year":"2014","unstructured":"Esposito S, Bruno C, Berardinelli A, Filosto M, Mongini T, Morandi L et al (2014) Vaccination recommendations for patients with neuromuscular disease. Vaccine 32:5893\u20135900. https:\/\/doi.org\/10.1016\/j.vaccine.2014.09.003","journal-title":"Vaccine"},{"key":"11140_CR51","doi-asserted-by":"publisher","DOI":"10.1186\/s42466-020-00091-z","author":"F Pasqualin","year":"2020","unstructured":"Pasqualin F, Guidoni SV, Ermani M, Pegoraro E, Bonifati DM (2020) Outcome measures and treatment effectiveness in late onset myasthenia gravis. Neurol Res Pract. https:\/\/doi.org\/10.1186\/s42466-020-00091-z","journal-title":"Neurol Res Pract"},{"key":"11140_CR52","first-page":"31","volume":"2012","author":"EMA","year":"2012","unstructured":"EMA (2012) Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg) (CPMP\/BPWG\/143744\/2011 Rev.1). Guideline 2012:31","journal-title":"Guideline"},{"key":"11140_CR53","doi-asserted-by":"publisher","first-page":"361","DOI":"10.3233\/JND-200520","volume":"7","author":"SB Ramaswamy","year":"2020","unstructured":"Ramaswamy SB, Govindarajan R (2020) Covid-19 in refractory myasthenia gravis-a case report of successful outcome. J Neuromuscul Dis 7:361\u2013364. https:\/\/doi.org\/10.3233\/JND-200520","journal-title":"J Neuromuscul Dis"},{"key":"11140_CR54","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1002\/jmv.26550","volume":"93","author":"J Finsterer","year":"2021","unstructured":"Finsterer J, Scorza FA (2021) SARS-CoV-2 myopathy. J Med Virol 93:1852\u20131853. https:\/\/doi.org\/10.1002\/jmv.26550","journal-title":"J Med Virol"},{"key":"11140_CR55","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2020.106045","volume":"196","author":"S Singh","year":"2020","unstructured":"Singh S, Govindarajan R (2020) COVID-19 and generalized myasthenia gravis exacerbation: a case report. Clin Neurol Neurosurg 196:106045. https:\/\/doi.org\/10.1016\/j.clineuro.2020.106045","journal-title":"Clin Neurol Neurosurg"},{"key":"11140_CR56","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1002\/mus.27324","volume":"64","author":"P Businaro","year":"2021","unstructured":"Businaro P, Vaghi G, Marchioni E, Diamanti L, Arceri S, Bini P et al (2021) COVID-19 in patients with myasthenia gravis: epidemiology and disease course. Muscle Nerve 64:206\u2013211. https:\/\/doi.org\/10.1002\/mus.27324","journal-title":"Muscle Nerve"},{"key":"11140_CR57","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s13760-021-01662-w","volume":"121","author":"S \u017dupani\u0107","year":"2021","unstructured":"\u017dupani\u0107 S, Peri\u0107 \u0160itum M, Majdak M, Karaka\u0161 M, Ba\u0161i\u0107 S, Spori\u0161 D (2021) Case series of COVID-19 in patients with myasthenia gravis: a single institution experience. Acta Neurol Belg 121:1039\u20131044. https:\/\/doi.org\/10.1007\/s13760-021-01662-w","journal-title":"Acta Neurol Belg"},{"key":"11140_CR58","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fneur.2021.635747","volume":"12","author":"J Finsterer","year":"2021","unstructured":"Finsterer J, Scorza FA (2021) Perspectives of neuro-COVID: myasthenia. Front Neurol 12:1\u20135. https:\/\/doi.org\/10.3389\/fneur.2021.635747","journal-title":"Front Neurol"},{"key":"11140_CR59","doi-asserted-by":"publisher","first-page":"e2109","DOI":"10.1212\/WNL.0000000000011669","volume":"96","author":"G Sol\u00e9","year":"2021","unstructured":"Sol\u00e9 G, Mathis S, Friedman D, Salort-Campana E, Tard C, Bouhour F et al (2021) Impact of coronavirus disease 2019 in a French cohort of myasthenia gravis. Neurology 96:e2109\u2013e2120. https:\/\/doi.org\/10.1212\/WNL.0000000000011669","journal-title":"Neurology"},{"key":"11140_CR60","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/ejhpharm-2021-002933","volume":"2021","author":"A Ossato","year":"2021","unstructured":"Ossato A, Tessari R, Trabucchi C, Zuppini T, Realdon N, Marchesini F (2021) Comparison of medium-term adverse reactions induced by the first and second dose of mRNA BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine: a post-marketing Italian study conducted between 1 January and 28 February 2021. Eur J Hosp Pharm 2021:1\u20136. https:\/\/doi.org\/10.1136\/ejhpharm-2021-002933","journal-title":"Eur J Hosp Pharm"},{"key":"11140_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2807\/1560-7917.ES.2021.26.12.2100329\/","volume":"26","author":"S Subbarao","year":"2021","unstructured":"Subbarao S, Warrener LA, Hoschler K, Perry KR, Shute J, Whitaker H et al (2021) Robust antibody responses in 70\u201380-year-olds 3 weeks after the first or second doses of Pfizer\/BioNTech COVID-19 vaccine, United Kingdom, January to February 2021. Eurosurveillance 26:1\u20136. https:\/\/doi.org\/10.2807\/1560-7917.ES.2021.26.12.2100329\/","journal-title":"Eurosurveillance"},{"key":"11140_CR62","doi-asserted-by":"publisher","DOI":"10.1016\/J.EBIOM.2021.103401","author":"M Frieman","year":"2021","unstructured":"Frieman M, Harris AD, Herati RS, Krammer F, Mantovani A, Rescigno M et al (2021) SARS-CoV-2 vaccines for all but a single dose for COVID-19 survivors. EBioMedicine. https:\/\/doi.org\/10.1016\/J.EBIOM.2021.103401","journal-title":"EBioMedicine"},{"key":"11140_CR63","doi-asserted-by":"publisher","first-page":"283","DOI":"10.15585\/MMWR.MM7008E3","volume":"70","author":"J Gee","year":"2021","unstructured":"Gee J, Marquez P, Su J, Calvert GM, Liu R, Myers T et al (2021) First month of COVID-19 vaccine safety monitoring \u2014 United States December 14, 2020\u2013January 13, 2021. MMWR Morb Mortal Wkly Rep 70:283\u2013288. https:\/\/doi.org\/10.15585\/MMWR.MM7008E3","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"11140_CR64","doi-asserted-by":"publisher","first-page":"2100096","DOI":"10.2807\/1560-7917.ES.2021.26.6.2100096\/","volume":"26","author":"KA Jabal","year":"2021","unstructured":"Jabal KA, Ben-Amram H, Beiruti K, Batheesh Y, Sussan C, Zarka S et al (2021) Impact of age, ethnicity, sex and prior infection status on immunogenicity following a single dose of the BNT162b2 MRNA COVID-19 vaccine: real-world evidence from healthcare workers, Israel, December 2020 to January 2021. Eurosurveillance 26:2100096. https:\/\/doi.org\/10.2807\/1560-7917.ES.2021.26.6.2100096\/","journal-title":"Eurosurveillance"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11140-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-022-11140-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-022-11140-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,25]],"date-time":"2022-08-25T10:06:40Z","timestamp":1661422000000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-022-11140-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,3]]},"references-count":64,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022,8]]}},"alternative-id":["11140"],"URL":"https:\/\/doi.org\/10.1007\/s00415-022-11140-9","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,3]]},"assertion":[{"value":"16 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 April 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 April 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2022","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Missing Open Access funding information has been added in the Funding Note","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors state that there is no conflict of interest. The authors have no competing interests to declare that are relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"The study was conducted according to 1964 Declaration of Helsinki and its later amendments. Approval from ethical committee was waived because of the nature of the study (both review and retrospective).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}